Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Y-Alam some of the results for these trials (eg regeneron) are out soon. If the drug shows efficacy I can see them wanting an inhaled formulation. Patient cant self medicate, alot cheaper and more convenient then iv. Plus localised action and less chance of iv related side effects. If our patent is valid in this instance then we have a lot to look forward to. I have always been of the view that the market has never taken into account the value of our intellectual
Property. Especially the patient on oral/nasal mAB which are first in class in a massive mAB market
These larger companies are only jumping on or band wagon...way behind
Shiraz, with regards the trials mentioned it seems we are ahead of the game at the moment as we successfully completed our human trials last year and are about to start treating real Covid patients in San Paulo hospital Brazil in the next couple of weeks. Looking great from that perspective.
We have only human monoclonal antibody patent
They would, but the other critical point is we have the only fully human IL6 antibody
Would appreciate what people think here, I may be way off the mark.. so astrazenica, sanofi, Roche, Eli
Lilly are all trialing mAB antibodies for covid via iv or sub cut. We. Have the only ever granted patent for oral, nasal, inhaled mAB. So if they wanted an inhaler form of there drug would they need to come to us?
Nice find.Regeneron's monoclonal antibody trial should be reporting end of September sort of time.It has also been added to the uk's RECOVERY trial now.
https://www.reuters.com/article/health-coronavirus-regeneron-antibody/regenerons-antibody-drug-added-to-uk-recovery-trial-of-covid-treatments-idUSL8N2GB188
https://www.fiercepharma.com/pharma/regeneron-roche-s-covid-19-antibody-****tail-could-net-6b-sales-next-year-analyst
Another trial starting for mAb treatment for Covid 19. This is GlaxoSmithKline but they aren't expecting results until the 2nd half of 2021
https://www.dailymail.co.uk/news/article-8779203/Manchester-man-receive-experimental-arthritis-drug-trial-treat-Covid-19.html